Dopaminergic agent; levodopa/carbidopa combination

This page covers all Dopaminergic agent; levodopa/carbidopa combination drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Dopamine pathway; aromatic L-amino acid decarboxylase inhibition.

Targets

Dopamine pathway; aromatic L-amino acid decarboxylase inhibition

Phase 3 pipeline (1)

• IPX203 ER CD-LD · Impax Laboratories, LLC · Neurology
  IPX203 ER CD-LD is a combination extended-release formulation of carbidopa and levodopa designed to provide sustained dopaminergic replacement therapy for Parkinson's disease with reduced dosing frequency.

Patent intelligence

• dopaminergic agent patent landscape — aggregated cliff calendar, attackable patents, originator estates